Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study.

Adrichem ME, Bus SR, Wieske L, Mohammed H, Verhamme C, Hadden R, van Schaik IN, Eftimov F.

Eur J Neurol. 2019 Sep 30. doi: 10.1111/ene.14096. [Epub ahead of print]

PMID:
31571349
2.

Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.

Hartung HP, Mallick R, Bril V, Lewis RA, Sobue G, Lawo JP, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN; PATH study group.

Eur J Neurol. 2019 Aug 10. doi: 10.1111/ene.14056. [Epub ahead of print]

PMID:
31400231
3.

The Mini Mental State Examination does not accurately screen for objective cognitive impairment in Fabry Disease.

Körver S, van de Schraaf SAJ, Geurtsen GJ, Hollak CEM, van Schaik IN, Langeveld M.

JIMD Rep. 2019 May 20;48(1):53-59. doi: 10.1002/jmd2.12036. eCollection 2019 Jul.

4.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5):e590. doi: 10.1212/NXI.0000000000000590. eCollection 2019 Sep.

5.

How incremental video training did not guarantee implementation due to fluctuating population prevalence.

Vink P, Torensma B, Lucas C, Hollmann MW, van Schaik IN, Vermeulen H.

BMJ Open Qual. 2019 May 4;8(2):e000447. doi: 10.1136/bmjoq-2018-000447. eCollection 2019.

6.

Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy.

Lucke IM, Wieske L, van der Kooi AJ, van Schaik IN, Eftimov F, Verhamme C.

J Peripher Nerv Syst. 2019 Jun;24(2):174-179. doi: 10.1111/jns.12325. Epub 2019 May 29.

PMID:
31090121
7.

Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.

van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, Michalak Z, Barro C, van Schaik IN, Kuhle J, Eftimov F.

J Peripher Nerv Syst. 2019 Jun;24(2):187-194. doi: 10.1111/jns.12319. Epub 2019 Apr 29.

PMID:
30973667
8.

Muscle weakness in a S. pneumoniae sepsis mouse model.

Witteveen E, Wieske L, Manders E, Verhamme C, Ottenheijm CAC, Schultz MJ, van Schaik IN, Horn J.

Ann Transl Med. 2019 Jan;7(1):9. doi: 10.21037/atm.2018.12.45.

9.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group.

J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.

10.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.

Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group.

J Peripher Nerv Syst. 2019 Mar;24(1):72-79. doi: 10.1111/jns.12303. Epub 2019 Mar 1.

11.

Predictors of objective cognitive impairment and subjective cognitive complaints in patients with Fabry disease.

Körver S, Geurtsen GJ, Hollak CEM, van Schaik IN, Longo MGF, Lima MR, Vedolin L, Dijkgraaf MGW, Langeveld M.

Sci Rep. 2019 Jan 17;9(1):188. doi: 10.1038/s41598-018-37320-0.

12.

Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy.

Lucke IM, Adrichem ME, Wieske L, van der Kooi AJ, Verhamme C, van Schaik IN, Eftimov F.

J Neurol Sci. 2019 Feb 15;397:141-145. doi: 10.1016/j.jns.2018.12.036. Epub 2018 Dec 31.

PMID:
30623818
13.

Development and clinical consequences of white matter lesions in Fabry disease: a systematic review.

Körver S, Vergouwe M, Hollak CEM, van Schaik IN, Langeveld M.

Mol Genet Metab. 2018 Nov;125(3):205-216. doi: 10.1016/j.ymgme.2018.08.014. Epub 2018 Sep 5.

PMID:
30213639
14.

Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone.

van Lieverloo GGA, Peric S, Doneddu PE, Gallia F, Nikolic A, Wieske L, Verhamme C, van Schaik IN, Nobile-Orazio E, Basta I, Eftimov F.

J Neurol. 2018 Sep;265(9):2052-2059. doi: 10.1007/s00415-018-8948-y. Epub 2018 Jul 2.

15.

No association between systemic complement activation and intensive care unit-acquired weakness.

Witteveen E, Wieske L, de Beer FM, Juffermans NP, Verhamme C, Schultz MJ, van Schaik IN, Horn J; BASIC study group.

Ann Transl Med. 2018 Apr;6(7):115. doi: 10.21037/atm.2018.01.30.

16.

Early Prediction of Intensive Care Unit-Acquired Weakness: A Multicenter External Validation Study.

Witteveen E, Wieske L, Sommers J, Spijkstra JJ, de Waard MC, Endeman H, Rijkenberg S, de Ruijter W, Sleeswijk M, Verhamme C, Schultz MJ, van Schaik IN, Horn J.

J Intensive Care Med. 2018 Jan 1:885066618771001. doi: 10.1177/0885066618771001. [Epub ahead of print]

PMID:
29716425
17.

Intravenous versus subcutaneous immunoglobulin - Authors' reply.

van Schaik IN, Mielke O; PATH study group.

Lancet Neurol. 2018 May;17(5):393-394. doi: 10.1016/S1474-4422(18)30109-1. No abstract available.

PMID:
29656738
18.

Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy.

Lucke IM, Peric S, van Lieverloo GGA, Wieske L, Verhamme C, van Schaik IN, Basta I, Eftimov F.

J Peripher Nerv Syst. 2018 Mar;23(1):49-54. doi: 10.1111/jns.12250. Epub 2018 Feb 6.

PMID:
29341326
19.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.

van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Erratum in: Lancet Neurol. 2018 Jan;17 (1):26. Erratum in: Lancet Neurol. 2018 Aug;17(8):661.

PMID:
29122523
20.

Drug therapy for chronic idiopathic axonal polyneuropathy.

Warendorf J, Vrancken AF, van Schaik IN, Hughes RA, Notermans NC.

Cochrane Database Syst Rev. 2017 Jun 20;6:CD003456. doi: 10.1002/14651858.CD003456.pub3. Review.

21.

Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series.

Adrichem ME, Starink MV, van Leeuwen EMM, Kramer C, van Schaik IN, Eftimov F.

J Peripher Nerv Syst. 2017 Sep;22(3):213-218. doi: 10.1111/jns.12218.

PMID:
28480635
22.

Diagnostic accuracy of quantitative neuromuscular ultrasound for the diagnosis of intensive care unit-acquired weakness: a cross-sectional observational study.

Witteveen E, Sommers J, Wieske L, Doorduin J, van Alfen N, Schultz MJ, van Schaik IN, Horn J, Verhamme C.

Ann Intensive Care. 2017 Dec;7(1):40. doi: 10.1186/s13613-017-0263-8. Epub 2017 Apr 5.

23.

Increased Early Systemic Inflammation in ICU-Acquired Weakness; A Prospective Observational Cohort Study.

Witteveen E, Wieske L, van der Poll T, van der Schaaf M, van Schaik IN, Schultz MJ, Verhamme C, Horn J; Molecular Diagnosis and Risk Stratification of Sepsis (MARS) Consortium.

Crit Care Med. 2017 Jun;45(6):972-979. doi: 10.1097/CCM.0000000000002408.

PMID:
28350642
24.

Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH.

Cochrane Database Syst Rev. 2017 Jan 13;1:CD010369. doi: 10.1002/14651858.CD010369.pub2. Review.

25.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.

van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G, Lawo JP, Mielke O, Cornblath DR, Merkies IS; PATH study group.

Trials. 2016 Jul 25;17(1):345. doi: 10.1186/s13063-016-1466-2.

26.

Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.

Adrichem ME, Eftimov F, van Schaik IN.

J Peripher Nerv Syst. 2016 Sep;21(3):121-7. doi: 10.1111/jns.12176. Review.

PMID:
27241239
27.

Erratum to: Pain management strategies for neuropathic pain in Fabry disease - a systematic review.

Schuller Y, Linthorst GE, Hollak CE, Van Schaik IN, Biegstraaten M.

BMC Neurol. 2016 May 16;16:67. doi: 10.1186/s12883-016-0590-7. No abstract available.

28.

Association between i.v. thrombolysis volume and door-to-needle times in acute ischemic stroke.

Groot AE, van Schaik IN, Visser MC, Nederkoorn PJ, Limburg M, Aramideh M, de Beer F, Zwetsloot CP, Halkes P, de Kruijk J, Kruyt ND, van der Meulen W, Spaander F, van der Ree T, Kwa VI, Van den Berg-Vos RM, Roos YB, Coutinho JM.

J Neurol. 2016 Apr;263(4):807-13. doi: 10.1007/s00415-016-8076-5. Epub 2016 Mar 5.

29.

Pain management strategies for neuropathic pain in Fabry disease--a systematic review.

Schuller Y, Linthorst GE, Hollak CE, Van Schaik IN, Biegstraaten M.

BMC Neurol. 2016 Feb 24;16:25. doi: 10.1186/s12883-016-0549-8. Review. Erratum in: BMC Neurol. 2016;16:67.

30.

In Patients with an α-Galactosidase A Variant, Small Nerve Fibre Assessment Cannot Confirm a Diagnosis of Fabry Disease.

van der Tol L, Verhamme C, van Schaik IN, van der Kooi AJ, Hollak CE, Biegstraaten M.

JIMD Rep. 2016;28:95-103. Epub 2015 Nov 14.

31.

Assessment of intensive care unit-acquired weakness in young and old mice: An E. coli septic peritonitis model.

Witteveen E, Hoogland IC, Wieske L, Weber NC, Verhamme C, Schultz MJ, van Schaik IN, Horn J.

Muscle Nerve. 2016 Jan;53(1):127-33. doi: 10.1002/mus.24711. Epub 2015 Nov 21.

32.

Impact of ICU-acquired weakness on post-ICU physical functioning: a follow-up study.

Wieske L, Dettling-Ihnenfeldt DS, Verhamme C, Nollet F, van Schaik IN, Schultz MJ, Horn J, van der Schaaf M.

Crit Care. 2015 Apr 27;19:196. doi: 10.1186/s13054-015-0937-2.

33.

Is gentamicin affecting the neuromuscular system of critically ill patients?

Wieske L, van Hest RM, Witteveen E, Verhamme C, Schultz MJ, van Schaik IN, Horn J.

Intensive Care Med. 2015 Apr;41(4):727-8. doi: 10.1007/s00134-015-3731-3. Epub 2015 Mar 10. No abstract available.

PMID:
25752304
34.

7th International Immunoglobulin Conference: Foreword.

Jolles S, Jordan SC, Orange JS, van Schaik IN.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:1-2. No abstract available.

35.

Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.

Brand M, Muller A, Alsop J, van Schaik IN, Bembi B, Hughes D.

Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):329-33. doi: 10.1002/pds.3760. Epub 2015 Feb 5.

PMID:
25656910
36.

Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Kerr J, Quinti I, Eibl M, Chapel H, Späth PJ, Sewell WA, Salama A, van Schaik IN, Kuijpers TW, Peter HH.

Front Immunol. 2014 Dec 12;5:629. doi: 10.3389/fimmu.2014.00629. eCollection 2014. Review.

37.

Immunoglobulins: current understanding and future directions.

Jolles S, Jordan SC, Orange JS, van Schaik IN.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:163-8. doi: 10.1111/cei.12555. No abstract available.

38.

Feasibility and diagnostic accuracy of early electrophysiological recordings for ICU-acquired weakness: an observational cohort study.

Wieske L, Verhamme C, Witteveen E, Bouwes A, Dettling-Ihnenfeldt DS, van der Schaaf M, Schultz MJ, van Schaik IN, Horn J.

Neurocrit Care. 2015 Jun;22(3):385-94. doi: 10.1007/s12028-014-0066-9.

PMID:
25403763
39.

Early prediction of intensive care unit-acquired weakness using easily available parameters: a prospective observational study.

Wieske L, Witteveen E, Verhamme C, Dettling-Ihnenfeldt DS, van der Schaaf M, Schultz MJ, van Schaik IN, Horn J.

PLoS One. 2014 Oct 27;9(10):e111259. doi: 10.1371/journal.pone.0111259. eCollection 2014.

40.

Effects of early and late diabetic neuropathy on sciatic nerve block duration and neurotoxicity in Zucker diabetic fatty rats.

Lirk P, Verhamme C, Boeckh R, Stevens MF, ten Hoope W, Gerner P, Blumenthal S, de Girolami U, van Schaik IN, Hollmann MW, Picardi S.

Br J Anaesth. 2015 Feb;114(2):319-26. doi: 10.1093/bja/aeu270. Epub 2014 Aug 21.

41.

Muscle and nerve inflammation in intensive care unit-acquired weakness: a systematic translational review.

Witteveen E, Wieske L, Verhamme C, Schultz MJ, van Schaik IN, Horn J.

J Neurol Sci. 2014 Oct 15;345(1-2):15-25. doi: 10.1016/j.jns.2014.07.014. Epub 2014 Jul 16. Review.

PMID:
25128472
42.

Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy.

Van De Vlekkert J, Maas M, Hoogendijk JE, De Visser M, Van Schaik IN.

Muscle Nerve. 2015 Feb;51(2):253-8. doi: 10.1002/mus.24307.

PMID:
24895239
43.

Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern.

Eftimov F, Liesdek MH, Verhamme C, van Schaik IN; PREDICT study group.

BMC Neurol. 2014 Apr 4;14:72. doi: 10.1186/1471-2377-14-72.

44.

Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study.

Wieske L, Witteveen E, Petzold A, Verhamme C, Schultz MJ, van Schaik IN, Horn J.

Crit Care. 2014 Jan 20;18(1):R18. doi: 10.1186/cc13699.

45.

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN.

Cochrane Database Syst Rev. 2013 Dec 30;(12):CD001797. doi: 10.1002/14651858.CD001797.pub3. Review.

PMID:
24379104
46.

Fabry disease: a rare cause of neuropathic pain.

Biegstraaten M, Linthorst GE, van Schaik IN, Hollak CE.

Curr Pain Headache Rep. 2013 Oct;17(10):365. doi: 10.1007/s11916-013-0365-4. Review.

PMID:
23996721
47.

Autonomic dysfunction in ICU-acquired weakness: a prospective observational pilot study.

Wieske L, Chan Pin Yin DR, Verhamme C, Schultz MJ, van Schaik IN, Horn J.

Intensive Care Med. 2013 Sep;39(9):1610-7. doi: 10.1007/s00134-013-2991-z. Epub 2013 Jun 21.

PMID:
23793889
48.

Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy.

Kuitwaard K, van Doorn PA, Vermeulen M, van den Berg LH, Brusse E, van der Kooi AJ, van der Pol WL, van Schaik IN, Notermans N, Tio-Gillen AP, van Rijs W, van Gelder T, Jacobs BC.

J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):859-61. doi: 10.1136/jnnp-2012-304670. Epub 2013 Mar 28.

PMID:
23538070
49.

Examination of cardiovascular and peripheral autonomic function in the ICU: a pilot study.

Wieske L, Kiszer ER, Schultz MJ, Verhamme C, van Schaik IN, Horn J.

J Neurol. 2013 Jun;260(6):1511-7. doi: 10.1007/s00415-012-6818-6. Epub 2012 Dec 30.

PMID:
23275003
50.

The long-term follow-up of treatment with corticosteroid injections in patients with carpal tunnel syndrome. When are multiple injections indicated?

Berger M, Vermeulen M, Koelman JH, van Schaik IN, Roos YB.

J Hand Surg Eur Vol. 2013 Jul;38(6):634-9. doi: 10.1177/1753193412469580. Epub 2012 Dec 6.

PMID:
23221180

Supplemental Content

Loading ...
Support Center